These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 7542009)
21. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. Tuveson DA; Ahearn JM; Matsumoto AK; Fearon DT J Exp Med; 1991 May; 173(5):1083-9. PubMed ID: 1708808 [TBL] [Abstract][Full Text] [Related]
22. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Hebell T; Ahearn JM; Fearon DT Science; 1991 Oct; 254(5028):102-5. PubMed ID: 1718035 [TBL] [Abstract][Full Text] [Related]
23. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Tedder TF; Poe JC; Fujimoto M; Haas KM; Sato S Curr Dir Autoimmun; 2005; 8():55-90. PubMed ID: 15564717 [TBL] [Abstract][Full Text] [Related]
24. Ligation of TAPA-1 (CD81) or major histocompatibility complex class II in co-cultures of human B and T lymphocytes enhances interleukin-4 synthesis by antigen-specific CD4+ T cells. Secrist H; Levy S; DeKruyff RH; Umetsu DT Eur J Immunol; 1996 Jul; 26(7):1435-42. PubMed ID: 8766544 [TBL] [Abstract][Full Text] [Related]
25. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. Kansas GS; Tedder TF J Immunol; 1991 Dec; 147(12):4094-102. PubMed ID: 1721639 [TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142 [TBL] [Abstract][Full Text] [Related]
27. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins. Rayhel EJ; Dehoff MH; Holers VM J Immunol; 1991 Mar; 146(6):2021-6. PubMed ID: 1706386 [TBL] [Abstract][Full Text] [Related]
28. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Chalupny NJ; Aruffo A; Esselstyn JM; Chan PY; Bajorath J; Blake J; Gilliland LK; Ledbetter JA; Tepper MA Eur J Immunol; 1995 Oct; 25(10):2978-84. PubMed ID: 7589101 [TBL] [Abstract][Full Text] [Related]
29. Integration of activatory and inhibitory signals in human B-cells. Sármay G; Koncz G; Gergely J Immunol Lett; 1996 Dec; 54(2-3):93-100. PubMed ID: 9052860 [TBL] [Abstract][Full Text] [Related]
30. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. Lederman S; Yellin MJ; Inghirami G; Lee JJ; Knowles DM; Chess L J Immunol; 1992 Dec; 149(12):3817-26. PubMed ID: 1281189 [TBL] [Abstract][Full Text] [Related]
31. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. Lee Y; Haas KM; Gor DO; Ding X; Karp DR; Greenspan NS; Poe JC; Tedder TF J Immunol; 2005 Dec; 175(12):8011-23. PubMed ID: 16339538 [TBL] [Abstract][Full Text] [Related]
32. The signaling activity of murine CD19 is regulated during cell development. Krop I; Shaffer AL; Fearon DT; Schlissel MS J Immunol; 1996 Jul; 157(1):48-56. PubMed ID: 8683154 [TBL] [Abstract][Full Text] [Related]
33. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Rickert RC Curr Opin Immunol; 2005 Jun; 17(3):237-43. PubMed ID: 15886112 [TBL] [Abstract][Full Text] [Related]
34. Lack of induced co-stimulation as a result of complement receptor 2 (CR2) ligation on mouse splenic B cells. Brown SL; Barrault DV; Phythian-Adams A; Knight AM Int Immunol; 2006 Jan; 18(1):69-78. PubMed ID: 16291653 [TBL] [Abstract][Full Text] [Related]
35. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Kulik L; Chen K; Huber BT; Holers VM Mol Immunol; 2011 Mar; 48(6-7):883-94. PubMed ID: 21269698 [TBL] [Abstract][Full Text] [Related]
36. Targeting antigen to CD19 on B cells efficiently activates T cells. Yan J; Wolff MJ; Unternaehrer J; Mellman I; Mamula MJ Int Immunol; 2005 Jul; 17(7):869-77. PubMed ID: 15967786 [TBL] [Abstract][Full Text] [Related]
37. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Carter RH; Fearon DT Science; 1992 Apr; 256(5053):105-7. PubMed ID: 1373518 [TBL] [Abstract][Full Text] [Related]
38. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction. Poe JC; Hasegawa M; Tedder TF Int Rev Immunol; 2001; 20(6):739-62. PubMed ID: 11913948 [TBL] [Abstract][Full Text] [Related]
39. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human cell surface triggers pp60src and Akt-GSK3 activities upstream and downstream to PI 3-kinase, respectively. Barel M; Balbo M; Le Romancer M; Frade R Eur J Immunol; 2003 Sep; 33(9):2557-66. PubMed ID: 12938232 [TBL] [Abstract][Full Text] [Related]